Acumen Pharmaceuticals Appoints Biotech Veteran George Golumbeski, Ph.D., As Chairman Of The Board To Guide Alzheimer’s Drug Development And Strategic Growth

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for Alzheimer’s disease, has announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board of Directors. With this appointment, Acumen’s Board now comprises eight members. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceutical industry, specializing in portfolio strategy, strategic collaborations, licensing, and mergers and acquisitions.

Acumen Pharmaceuticals is dedicated to developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs), which are believed to play a key role in the progression of Alzheimer’s disease. The company’s current lead program includes the ongoing Phase 2 clinical trial of sabirnetug and its Enhanced Brain Delivery program, both designed to deliver disease-modifying treatments for Alzheimer’s patients.

Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals, welcomed Dr. Golumbeski’s appointment, highlighting his extensive leadership experience and strategic insight. “We are very pleased to have Dr. Golumbeski join the Acumen Board as we continue our mission to develop novel, disease-modifying treatments for Alzheimer’s disease,” O’Connell said. “He has a remarkable record of building strategic partnerships and driving collaborations that have led to the development of transformative therapies. His expertise aligns closely with our current growth trajectory as we look ahead to key milestones in our ongoing Phase 2 trial of sabirnetug and the continued progress of our Enhanced Brain Delivery program. Both initiatives hold great promise for improving the lives of people with Alzheimer’s and creating long-term value for our shareholders.”

Expressing his enthusiasm for joining the Board, Dr. Golumbeski emphasized the importance of innovation in addressing the unmet needs of patients living with Alzheimer’s. “Having witnessed how scientific innovation can profoundly impact patients with difficult-to-treat diseases, I am honored to join Acumen at such a pivotal stage in its development,” he said. “The unmet need in Alzheimer’s disease remains enormous, and the field is reaching a critical turning point. I look forward to working with the Board, leadership, and the entire Acumen team to advance the company’s programs and help improve the lives of patients with early Alzheimer’s, as well as their families and caregivers.”

Dr. Golumbeski is currently involved with DROIA Ventures, a specialist biotech investment firm where he helps guide the development of emerging life sciences companies. He previously served for nearly a decade as Executive Vice President of Business Development at Celgene, where he was instrumental in forming strategic partnerships with biotechnology companies to deliver groundbreaking therapies for cancer and chronic inflammatory diseases. Prior to his tenure at Celgene, he held senior business development positions at Novartis Pharmaceuticals and Elan Pharmaceuticals, where he focused on neurology and neurodegenerative diseases.

Dr. Golumbeski earned his Ph.D. in Genetics from the University of Wisconsin–Madison and completed his postdoctoral research in molecular biology at the University of Colorado–Boulder. He also holds a Bachelor of Arts in Biology from the University of Virginia. His deep scientific expertise, combined with decades of industry leadership, is expected to play an important role in guiding Acumen’s strategic direction as the company advances its mission to transform Alzheimer’s care through science-driven innovation.